arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Cytosorbents Corp

CTSO
$4.60 ▲ +0.19 (+4.31%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
29 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cytosorbents Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $286.3M
Dividend Yield —
Revenue Growth 4.1% ↗
Op. Margin -39.8% ↗
ROIC -62.3% ↘
FCF / Share $-0.20 ↗
Trailing P/E —
Price / Book 48.9x
FCF Yield —
Debt / Equity 2.82
info Valuation on last close. End-of-day price, Nov 5, 2026.

29-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$37.06M
↑ +4.1% —
Net Income Profit after all expenses
$-8.20M
↑ +60.4% —
Operating Margin Operating profit as % of sales
-39.8%
↑ +13.9% 6th
FCF / Share Free cash flow per share
$-0.20
↑ +25.4% —
Long-Term Debt Long-term obligations
$16.67M
↑ +19.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
8
Returns ↓
6
Financial Health →
21
Cash Quality ↑
81

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 29 years · 80 quarters